Prediction of violent reoffending in prisoners and individuals on probation: a Dutch validation study (OxRec).


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
29 01 2019
Historique:
received: 24 04 2018
accepted: 07 12 2018
entrez: 31 1 2019
pubmed: 31 1 2019
medline: 5 8 2020
Statut: epublish

Résumé

Scalable and transparent methods for risk assessment are increasingly required in criminal justice to inform decisions about sentencing, release, parole, and probation. However, few such approaches exist and their validation in external settings is typically lacking. A total national sample of all offenders (9072 released from prisoners and 6329 individuals on probation) from 2011-2012 in the Netherlands were followed up for violent and any reoffending over 2 years. The sample was mostly male (n = 574 [6%] were female prisoners and n = 784 [12%] were female probationers), and median ages were 30 in the prison sample and 34 in those on probation. Predictors for a scalable risk assessment tool (OxRec) were extracted from a routinely collected dataset used by criminal justice agencies, and outcomes from official criminal registers. OxRec's predictive performance in terms of discrimination and calibration was tested. Reoffending rates in the Dutch prisoner cohort were 16% for 2-year violent reoffending and 44% for 2-year any reoffending, with lower rates in the probation sample. Discrimination as measured by the c-index was moderate, at 0.68 (95% CI: 0.66-0.70) for 2-year violent reoffending in prisoners and between 0.65 and 0.68 for other outcomes and the probation sample. The model required recalibration, after which calibration performance was adequate (e.g. calibration in the large was 1.0 for all scenarios). A recalibrated model for OxRec can be used in the Netherlands for individuals released from prison and individuals on probation to stratify their risk of future violent and any reoffending. The approach that we outline can be considered for external validations of criminal justice and clinical risk models.

Identifiants

pubmed: 30696902
doi: 10.1038/s41598-018-37539-x
pii: 10.1038/s41598-018-37539-x
pmc: PMC6351626
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

841

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202836/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust (Wellcome)
ID : 202836/Z/16/Z
Pays : International

Références

Stat Med. 2000 Dec 30;19(24):3401-15
pubmed: 11122504
Behav Sci Law. 2006;24(6):799-813
pubmed: 17171770
Stat Med. 2009 Jul 10;28(15):1982-98
pubmed: 19452569
Assessment. 2010 Sep;17(3):377-95
pubmed: 20124429
PLoS Med. 2012;9(5):1-12
pubmed: 22629234
BMJ. 2012 Jul 24;345:e4692
pubmed: 22833604
Br J Psychiatry. 2013 May;202(5):365-71
pubmed: 23520222
Int J Epidemiol. 2013 Aug;42(4):1057-66
pubmed: 24062294
Br J Psychiatry. 2013 Nov;203(5):387-8
pubmed: 24072757
Br J Psychiatry. 2014 Mar;204(3):180-7
pubmed: 24590974
BMC Med Res Methodol. 2014 Mar 19;14:40
pubmed: 24645774
J Forensic Psychol Pract. 2016 Jan 1;16(1):49-59
pubmed: 26924945
Lancet Psychiatry. 2016 Jun;3(6):535-43
pubmed: 27086134
Psychol Serv. 2016 Aug;13(3):206-22
pubmed: 27267819
Stat Methods Med Res. 2018 Jan;27(1):185-197
pubmed: 27460537
Law Hum Behav. 2017 Feb;41(1):29-43
pubmed: 27936826
Lancet Psychiatry. 2017 Jun;4(6):461-468
pubmed: 28479143
Evid Based Ment Health. 2018 May;21(2):41-43
pubmed: 29269440
J Clin Epidemiol. 2018 Nov;103:131-133
pubmed: 30063954
J Clin Epidemiol. 1996 Dec;49(12):1373-9
pubmed: 8970487

Auteurs

Seena Fazel (S)

Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK. seena.fazel@psych.ox.ac.uk.

Achim Wolf (A)

Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, UK.

Maria D L A Vazquez-Montes (MDLA)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Thomas R Fanshawe (TR)

Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH